Establishment Labs (NASDAQ:ESTA) Sets New 52-Week High – What’s Next?

Establishment Labs Holdings Inc. (NASDAQ:ESTA)’s stock price reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $86.00 and last traded at $85.2260, with a volume of 59029 shares. The stock had previously closed at $82.39.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ESTA shares. BTIG Research upped their price objective on Establishment Labs from $88.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Needham & Company LLC upped their price objective on Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. Citigroup reaffirmed a “neutral” rating on shares of Establishment Labs in a research report on Wednesday, May 6th. Canaccord Genuity Group upped their price objective on Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Establishment Labs in a research report on Monday, June 8th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Establishment Labs has a consensus rating of “Moderate Buy” and a consensus price target of $87.14.

Establishment Labs Trading Up 2.3%

The stock has a market capitalization of $2.48 billion, a price-to-earnings ratio of -56.60 and a beta of 1.11. The company has a debt-to-equity ratio of 16.82, a quick ratio of 1.91 and a current ratio of 2.96. The business has a 50-day moving average of $70.25 and a 200-day moving average of $69.48.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). The firm had revenue of $59.88 million during the quarter, compared to analyst estimates of $57.40 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The firm’s revenue for the quarter was up 44.7% compared to the same quarter last year. During the same period last year, the company earned ($0.70) earnings per share. As a group, research analysts forecast that Establishment Labs Holdings Inc. will post -1.07 EPS for the current year.

Insider Activity

In related news, Director Quiros Juan Jose Chacon sold 105,000 shares of the company’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total value of $7,919,100.00. Following the completion of the sale, the director directly owned 927,504 shares of the company’s stock, valued at $69,952,351.68. This represents a 10.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders sold 330,000 shares of company stock valued at $22,854,538. 9.99% of the stock is owned by corporate insiders.

Institutional Trading of Establishment Labs

Large investors have recently made changes to their positions in the company. KBC Group NV acquired a new stake in shares of Establishment Labs in the 1st quarter valued at about $28,000. Kestra Advisory Services LLC acquired a new stake in Establishment Labs during the 4th quarter worth approximately $47,000. Quarry LP acquired a new stake in Establishment Labs during the 3rd quarter worth approximately $34,000. MV Capital Management Inc. acquired a new stake in Establishment Labs during the 4th quarter worth approximately $146,000. Finally, Osaic Holdings Inc. lifted its position in Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after acquiring an additional 1,800 shares during the period. 72.91% of the stock is owned by institutional investors and hedge funds.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.